Attitudes and beliefs toward the use of stereotactic body radiotherapy in oligometastatic breast cancer: A commentary on a survey of Canadian Medical Oncologists
- 1 July 2019
- journal article
- research article
- Published by Hindawi Limited in The Breast Journal
- Vol. 25 (6) , 1222-1224
Abstract
Stereotactic body radiotherapy (SBRT) is a highly ablative local therapy which has emerged as part of the treatment paradigm for patients with oligometastatic (OM) breast cancer (defined by 5 or fewer sites). This patient group has demonstrated improved prognosis in some cases and may therefore, benefit from aggressive local treatment. The role of upfront SBRT in newly diagnosed OM breast cancer in addition to systemic therapy is not clear, yet it is being increasingly utilized within the oncology community. The Canadian medical system is an ideal platform in which to investigate SBRT into the OM breast cancer setting, as it is not routinely implemented across centers at this time, as there is potential for robust collaboration between oncologists in the small community to investigate SBRT, and there is limited financial or industry motivation for early SBRT uptake compared with other countries. It is critical therefore to define the optimal patient population and scenarios for which SBRT should be investigated, as well as offered in the interim to Canadian patients. We therefore conducted a survey of Canadian Medical Oncologists, the primary physicians and gatekeepers of patients with OM breast cancer, to characterize their beliefs, opinions, and areas of controversy in the use of SBRT for OM breast cancer.Keywords
This publication has 8 references indexed in Scilit:
- Radical radiation therapy for oligometastatic breast cancer: Results of a prospective phase II trialRadiotherapy and Oncology, 2018
- Identifying Barriers to Accrual in Radiation Oncology Randomized TrialsCurrent Oncology, 2017
- Ablative Therapies in Metastatic Breast Cancer: A Systematic ReviewBreast Cancer Research and Treatment, 2017
- Role of Local Ablative Therapy in Patients with Oligometastatic and Oligoprogressive Non–Small Cell Lung CancerJournal of Thoracic Oncology, 2017
- NRG BR002: A phase IIR/III trial of standard of care therapy with or without stereotactic body radiotherapy (SBRT) and/or surgical ablation for newly oligometastatic breast cancer.Journal of Clinical Oncology, 2015
- Oligometastases Treated With Stereotactic Body Radiotherapy: Long-Term Follow-Up of Prospective StudyInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2012
- Long-term local control achieved after hypofractionated stereotactic body radiotherapy for adrenal gland metastases: A retrospective analysis of 34 patientsActa Oncologica, 2012
- Metastatic Behavior of Breast Cancer SubtypesJournal of Clinical Oncology, 2010